Cryoport Toekomstige groei
Future criteriumcontroles 0/6
Cryoport zal naar verwachting groeien in winst en omzet met respectievelijk 13.7% en 9.5% per jaar. De winst per aandeel zal naar verwachting groeien met 16.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -9.5% zijn.
Belangrijke informatie
13.7%
Groei van de winst
16.69%
Groei van de winst per aandeel
| Life Sciences winstgroei | 16.9% |
| Inkomstengroei | 9.5% |
| Toekomstig rendement op eigen vermogen | -9.55% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 08 Jun 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Jun 26
CYRX: Bioservices Demand And Service Mix Will Drive Future Upside
The analyst price target for Cryoport has been raised from $16.00 to about $19.93. Analysts cite stronger expected revenue growth, slightly higher margin assumptions, and a modestly lower future P/E multiple as key factors behind their updated view.
Narratiefupdate • Jun 12
CYRX: Differentiated Bioservices And Regulatory Support Will Shape Balanced Forward Outlook
Cryoport's analyst price target has moved up by $2 to $15.61, with analysts pointing to stronger appreciation for its differentiated bioservices offering, higher perceived revenue visibility and margin potential, and ongoing regulatory and funding support for growth as key drivers of their updated views. Analyst Commentary Recent research updates have centered on Cryoport's bioservices operations, with several firms revisiting their valuation frameworks after site visits and a review of end market conditions.
Narratiefupdate • May 29
CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution
Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.Narratiefupdate • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.Narratiefupdate • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.Narratiefupdate • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.Narratiefupdate • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.Narratiefupdate • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).Narratiefupdate • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).Narratiefupdate • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).Narratiefupdate • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.Narratiefupdate • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.Narratiefupdate • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.Narratiefupdate • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.Narratiefupdate • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.Narratiefupdate • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.Narratiefupdate • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.Analyseartikel • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...Analyseartikel • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...Analyseartikel • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Nieuw narratief • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Analyseartikel • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...Analyseartikel • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...Analyseartikel • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 234 | -28 | 20 | 43 | 4 |
| 12/31/2027 | 213 | -33 | -9 | 9 | 9 |
| 12/31/2026 | 194 | -39 | -25 | -5 | 9 |
| 3/31/2026 | 183 | -45 | -26 | -1 | N/A |
| 12/31/2025 | 176 | -42 | -28 | -9 | N/A |
| 9/30/2025 | 172 | -48 | -35 | -15 | N/A |
| 6/30/2025 | 166 | -38 | -38 | -17 | N/A |
| 3/31/2025 | 161 | -104 | -38 | -17 | N/A |
| 12/31/2024 | 157 | -113 | -38 | -16 | N/A |
| 9/30/2024 | 173 | -158 | -36 | -8 | N/A |
| 6/30/2024 | 190 | -175 | -45 | -11 | N/A |
| 3/31/2024 | 208 | -117 | -46 | -7 | N/A |
| 12/31/2023 | 169 | -93 | -46 | -1 | N/A |
| 9/30/2023 | 236 | -55 | -41 | 0 | N/A |
| 6/30/2023 | 241 | -47 | -32 | 3 | N/A |
| 3/31/2023 | 248 | -38 | -29 | 0 | N/A |
| 12/31/2022 | 237 | -45 | -26 | -2 | N/A |
| 9/30/2022 | 233 | -296 | -27 | -3 | N/A |
| 6/30/2022 | 230 | -297 | -23 | 5 | N/A |
| 3/31/2022 | 222 | -293 | -12 | 15 | N/A |
| 12/31/2021 | 223 | -284 | -17 | 8 | N/A |
| 9/30/2021 | 215 | -76 | -25 | -4 | N/A |
| 6/30/2021 | 169 | -78 | -32 | -18 | N/A |
| 3/31/2021 | 122 | -77 | -34 | -22 | N/A |
| 12/31/2020 | 79 | -75 | -25 | -15 | N/A |
| 9/30/2020 | 40 | -22 | -11 | -4 | N/A |
| 6/30/2020 | 38 | -23 | -6 | 0 | N/A |
| 3/31/2020 | 37 | -20 | -5 | 0 | N/A |
| 12/31/2019 | 34 | -18 | N/A | -1 | N/A |
| 9/30/2019 | 30 | -20 | N/A | -2 | N/A |
| 6/30/2019 | 26 | -9 | N/A | -2 | N/A |
| 3/31/2019 | 22 | -9 | N/A | -2 | N/A |
| 12/31/2018 | 20 | -10 | N/A | -3 | N/A |
| 9/30/2018 | 17 | -10 | N/A | -4 | N/A |
| 6/30/2018 | 15 | -9 | N/A | -5 | N/A |
| 3/31/2018 | 13 | -9 | N/A | -4 | N/A |
| 12/31/2017 | 12 | -8 | N/A | -4 | N/A |
| 9/30/2017 | 11 | -10 | N/A | -3 | N/A |
| 6/30/2017 | 10 | -10 | N/A | -4 | N/A |
| 3/31/2017 | 9 | -12 | N/A | -5 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -6 | N/A |
| 9/30/2016 | 7 | -12 | N/A | -6 | N/A |
| 6/30/2016 | 6 | -12 | N/A | -6 | N/A |
| 3/31/2016 | 6 | -15 | N/A | -6 | N/A |
| 12/31/2015 | 6 | -16 | N/A | -6 | N/A |
| 9/30/2015 | 5 | -15 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van CYRX ( 9.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 12.7% per jaar).
Hoge groei-inkomsten: De omzet van CYRX ( 9.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat CYRX binnen 3 jaar verliesgevend zal zijn.
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 00:59 |
| Aandelenkoers aan het einde van de dag | 2026/06/30 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cryoport, Inc. wordt gevolgd door 14 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |